#South Korea #Seoul #AI Solutions #Neurophet #Alzheimers

Neurophet Showcases Advanced Imaging Solutions for Alzheimer’s Disease at AAIC 2025

On July 31, 2025, Neurophet, an innovative company focused on artificial intelligence solutions for brain disorders, made headlines at the Alzheimer’s Association International Conference (AAIC 2025) held in Toronto, Canada. Co-CEOs Jake Junkil Been and Donghyeon Kim led the exhibition, where the company unveiled its flagship product, Neurophet AQUA AD, a comprehensive neuroimaging analysis software designed specifically for Alzheimer’s disease.

The Presentation

During the event, Jake Junkil Been presented a talk titled Neurophet in the Era of Paradigm Shift in Alzheimer's Disease: The Journey to IPO and Beyond. He articulated the revolutionary potential of Neurophet's technologies, showcasing their mission to reshape diagnostic methodologies and treatment frameworks in neurology.

Introducing Neurophet AQUA AD

Neurophet AQUA AD is a state-of-the-art solution designed to meticulously monitor the effects of Alzheimer's treatments, particularly those targeting amyloid plaques. With its ability to analyze both MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans, this software provides healthcare professionals with in-depth insights into the brain's response to therapeutic interventions. By quantitatively assessing changes throughout the treatment process, Neurophet AQUA AD allows for a robust evaluation of the efficacy of anti-amyloid antibody therapies such as Leqembi® (lecanemab) and Kisunla® (donanemab).

As the pharmaceutical and biotech industries accelerate their efforts to develop effective treatments for Alzheimer’s, the need for advanced software that can accurately track prescription patterns, therapeutic effectiveness, and potential side effects has never been more crucial. Neurophet AQUA AD rises to the challenge, gaining attention from healthcare providers anticipating the intricate demands of managing Alzheimer's therapies.

Engagement with Global Pharmaceuticals

At AAIC 2025, Neurophet’s booth also featured several other groundbreaking products, including Neurophet AQUA, a neurodegeneration imaging analysis software, and Neurophet SCALE PET, dedicated to quantitative analysis of PET imaging. These innovations not only underline Neurophet’s commitment to advancing the field of neurology but also highlight its eagerness to collaborate with global pharmaceutical giants and key opinion leaders (KOLs) in the sector.

Jake Junkil Been emphasized the growing recognition of Neurophet AQUA AD as a valuable partner among international entities in brain imaging. He remarked, “Through our participation in AAIC 2025, we aim to foster strategic partnerships that will accelerate global development opportunities for Neurophet AQUA AD and our other core offerings.”

Looking Ahead

The AAIC 2025 conference brought together leading dementia researchers and clinicians, creating an invaluable platform for sharing knowledge and fostering collaboration. With a five-day schedule from July 27 to 31, this event cast a spotlight on the urgent need for innovation in Alzheimer’s care. Neurophet's approach may very well pave the way for more personalized and effective treatment plans in the future.

Founded in 2016, Neurophet has continually pushed the boundaries of what is achievable in brain disorder diagnosis and management. Its portfolio includes a variety of AI-driven tools aimed at providing comprehensive support for both clinicians and patients alike. As the company progresses, its unwavering focus on addressing the complexities of brain health remains at the forefront of its mission.

In closing, Neurophet’s presence at AAIC 2025 signifies more than just a display of advanced technologies; it embodies a commitment to improving the quality of life for those affected by Alzheimer’s disease through innovation and collaboration, making strides toward a future where better diagnosis and treatment options are within reach for all patients.